CN101679318A - 使用链接化学法的用于碳酸酐酶-ix的分子成象探针的发展 - Google Patents

使用链接化学法的用于碳酸酐酶-ix的分子成象探针的发展 Download PDF

Info

Publication number
CN101679318A
CN101679318A CN200880010576A CN200880010576A CN101679318A CN 101679318 A CN101679318 A CN 101679318A CN 200880010576 A CN200880010576 A CN 200880010576A CN 200880010576 A CN200880010576 A CN 200880010576A CN 101679318 A CN101679318 A CN 101679318A
Authority
CN
China
Prior art keywords
methyl
alkyl
triazol
phenyl
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880010576A
Other languages
English (en)
Chinese (zh)
Inventor
H·C·科尔布
J·C·沃什
D·卡西
V·莫查拉
王兵
U·B·甘达哈马斯
B·A·杜克洛斯
陈凯
张炜
陈钢
H·C·帕吉特
F·卡里米
P·J·H·斯科特
高志勇
梁千瓦
T·L·柯利耶
赵铁铭
夏春芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Medical Solutions USA Inc
Original Assignee
Siemens Medical Solutions USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Medical Solutions USA Inc filed Critical Siemens Medical Solutions USA Inc
Publication of CN101679318A publication Critical patent/CN101679318A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880010576A 2007-04-05 2008-04-07 使用链接化学法的用于碳酸酐酶-ix的分子成象探针的发展 Pending CN101679318A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92206507P 2007-04-05 2007-04-05
US60/922,065 2007-04-05
PCT/US2008/059599 WO2008124703A2 (en) 2007-04-05 2008-04-07 Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry

Publications (1)

Publication Number Publication Date
CN101679318A true CN101679318A (zh) 2010-03-24

Family

ID=39743771

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880010576A Pending CN101679318A (zh) 2007-04-05 2008-04-07 使用链接化学法的用于碳酸酐酶-ix的分子成象探针的发展

Country Status (7)

Country Link
US (2) US7829063B2 (enExample)
EP (2) EP2129666A2 (enExample)
JP (1) JP2010523599A (enExample)
KR (2) KR20090127433A (enExample)
CN (1) CN101679318A (enExample)
CA (1) CA2683434A1 (enExample)
WO (1) WO2008124703A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219753A (zh) * 2011-04-21 2011-10-19 山东大学 一种三氮唑类化合物及其制备方法与应用
CN103380118A (zh) * 2010-10-29 2013-10-30 克林诺株式会社 Tau成像探针
CN104212440A (zh) * 2014-09-03 2014-12-17 无锡艾德美特生物科技有限公司 一类喹唑啉类荧光探针及其制备和应用
CN105541825A (zh) * 2015-12-28 2016-05-04 中国药科大学 三氮唑衍生物制备方法及其作为药物的用途
CN106243051A (zh) * 2010-11-13 2016-12-21 茵库恩制药有限公司 金属酶抑制剂化合物
CN107428776A (zh) * 2015-03-24 2017-12-01 H.隆德贝克有限公司 制造4,5,6,7‑四氢异噁唑并[5,4‑c]吡啶‑3‑醇
CN109476655A (zh) * 2016-05-13 2019-03-15 约翰霍普金斯大学 靶向碳酸酐酶ix的核成像剂和放射治疗剂及其用途
CN110997651A (zh) * 2017-08-17 2020-04-10 葛兰素史密斯克莱知识产权发展有限公司 新的四唑化合物和它们在治疗结核病中的用途
CN117986213A (zh) * 2024-02-26 2024-05-07 厦门大学 一种5-氯甲基糠醛制备2,5-二（氨基甲基）呋喃的方法
WO2025113696A1 (zh) * 2023-11-30 2025-06-05 赣州和美药业股份有限公司 一种化合物及其应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129440A1 (en) * 2007-10-29 2011-06-02 Schering Corporation Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof
CA2711678A1 (en) * 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
WO2011018798A2 (en) * 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
CN102574782B (zh) * 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
US9023316B2 (en) 2010-04-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Synthesis of 18F-labeled tracers in hydrous organic solvents
US10639608B2 (en) 2010-04-08 2020-05-05 Siemens Medical Solutions Usa, Inc. System, device and method for preparing tracers and transferring materials during radiosynthesis
US9180209B2 (en) * 2011-02-28 2015-11-10 The Board Of Trustees Of The Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
EP2707102B1 (en) 2011-05-09 2019-11-13 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
JP2014156400A (ja) * 2011-05-24 2014-08-28 Astellas Pharma Inc 腫瘍の画像診断用標識誘導体
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
EP2831264B1 (en) 2012-03-30 2019-07-10 VisEn Medical, Inc. Bacterial imaging agents and methods of using same
HUE035739T2 (en) 2013-01-14 2018-05-28 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radiological imaging agents
CA2929401A1 (en) 2013-11-05 2015-05-14 Bayer Cropscience Aktiengesellschaft Novel compounds for combating arthropods
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
CN107074860B (zh) * 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
US11358940B2 (en) * 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
KR102147971B1 (ko) * 2019-11-22 2020-08-25 국방과학연구소 반응용매에 대한 혼화성 차이를 이용한 화학선택적 트리아졸의 제조방법
WO2026060272A1 (en) * 2024-09-16 2026-03-19 Wisconsin Alumni Research Foundation Long-residence ca9 ligands and radioisotope carriers for inhibition, visualization and irradiation of ca9-expressing tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1569633A4 (en) * 2002-11-26 2008-03-05 Inst Virology CA-IX SPECIFIC HEMMER
EP1875239B1 (en) * 2005-04-27 2011-10-05 Siemens Medical Solutions USA, Inc. A method for the preparation of imaging probes using click chemistry
EP1733742A1 (en) 2005-06-17 2006-12-20 Universiteit Utrecht Holding B.V. Dendrimers multivalently substituted with active groups
EP1909846B1 (en) 2005-08-05 2018-12-26 Syntarga B.V. Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
WO2008027162A2 (en) * 2006-08-28 2008-03-06 The Trustees Of The University Of Pennsylvania 129xe biosensors and their use
WO2008033557A2 (en) 2006-09-15 2008-03-20 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclic peptidomimetics as integrin markers

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103380118A (zh) * 2010-10-29 2013-10-30 克林诺株式会社 Tau成像探针
CN106243051B (zh) * 2010-11-13 2019-03-08 茵库恩制药有限公司 金属酶抑制剂化合物
CN106243051A (zh) * 2010-11-13 2016-12-21 茵库恩制药有限公司 金属酶抑制剂化合物
CN102219753A (zh) * 2011-04-21 2011-10-19 山东大学 一种三氮唑类化合物及其制备方法与应用
CN104212440A (zh) * 2014-09-03 2014-12-17 无锡艾德美特生物科技有限公司 一类喹唑啉类荧光探针及其制备和应用
CN104212440B (zh) * 2014-09-03 2016-03-30 无锡艾德美特生物科技有限公司 一类喹唑啉类荧光探针及其制备和应用
CN107428776A (zh) * 2015-03-24 2017-12-01 H.隆德贝克有限公司 制造4,5,6,7‑四氢异噁唑并[5,4‑c]吡啶‑3‑醇
CN105541825A (zh) * 2015-12-28 2016-05-04 中国药科大学 三氮唑衍生物制备方法及其作为药物的用途
CN109476655A (zh) * 2016-05-13 2019-03-15 约翰霍普金斯大学 靶向碳酸酐酶ix的核成像剂和放射治疗剂及其用途
CN110997651A (zh) * 2017-08-17 2020-04-10 葛兰素史密斯克莱知识产权发展有限公司 新的四唑化合物和它们在治疗结核病中的用途
CN110997651B (zh) * 2017-08-17 2023-01-03 葛兰素史密斯克莱知识产权发展有限公司 新的四唑化合物和它们在治疗结核病中的用途
WO2025113696A1 (zh) * 2023-11-30 2025-06-05 赣州和美药业股份有限公司 一种化合物及其应用
CN117986213A (zh) * 2024-02-26 2024-05-07 厦门大学 一种5-氯甲基糠醛制备2,5-二（氨基甲基）呋喃的方法

Also Published As

Publication number Publication date
KR20120003499A (ko) 2012-01-10
WO2008124703A2 (en) 2008-10-16
CA2683434A1 (en) 2008-10-16
JP2010523599A (ja) 2010-07-15
EP2468734A1 (en) 2012-06-27
US20100317842A1 (en) 2010-12-16
US20090123372A1 (en) 2009-05-14
EP2129666A2 (en) 2009-12-09
US7829063B2 (en) 2010-11-09
US8354092B2 (en) 2013-01-15
WO2008124703A3 (en) 2009-02-05
KR20090127433A (ko) 2009-12-11

Similar Documents

Publication Publication Date Title
US8354092B2 (en) Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry
US20250122194A1 (en) Novel small molecule inhibitors of tead transcription factors
JP5347164B2 (ja) ニトロ−イミダゾール低酸素造影剤
ES2375495T3 (es) Un método para la preparación de sondas para la formación de im�?genes utilizando qu�?mica clic.
CN102083427B (zh) 碳酸酐酶ix的抑制剂
EP3870160A1 (en) Compounds and methods to attenuate tumor progression and metastasis
AU3871100A (en) Inhibitors of protein tyrosine phosphatase
JP2020520982A (ja) がん治療のためのイオンチャネル阻害剤化合物
US20220135572A1 (en) Compounds and methods for targeting hsp90
US12240855B2 (en) Pyrrolopyrazole derivative
US20230052551A1 (en) Fluorescent probe for detection of enpp activity
JP7774897B2 (ja) 窒素含有化合物、前記窒素含有化合物を含む組成物、及び腫瘍悪性度の予測マーカー
WO2019157959A1 (zh) 一种嘧啶类化合物、其制备方法及其医药用途
WO2012121285A1 (ja) 標識前駆体化合物、放射性標識化合物、及びそれらの製造方法
TW202235077A (zh) Usp7結合存活靶向嵌合(surtac)分子及其用途
Calder et al. The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat
BR112021018303B1 (pt) Composto inibidor de pequenas moléculas de fatores de transcrição de tead ou sal farmaceuticamente aceitável deste, composição farmacêutica e uso destes
HK40061019A (en) Pyrrolopyrazole derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100324